Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1998 Apr 1;101(7):1296–1300. doi: 10.1172/JCI1259

Increased expression of the sodium/iodide symporter in papillary thyroid carcinomas.

T Saito 1, T Endo 1, A Kawaguchi 1, M Ikeda 1, R Katoh 1, A Kawaoi 1, A Muramatsu 1, T Onaya 1
PMCID: PMC508706  PMID: 9525971

Abstract

Iodide is concentrated to a much lesser extent by papillary thyroid carcinoma as compared with the normal gland. The Na+/I- symporter (NIS) is primarily responsible for the uptake of iodide into thyroid cells. Our objective was to compare NIS mRNA and protein expression in papillary carcinomas with those in specimens with normal thyroid. Northern blot analysis revealed a 2.8-fold increase in the level of NIS mRNA in specimens with papillary carcinoma versus specimens with normal thyroid. Immunoblot analysis using anti-human NIS antibody that was produced with a glutathione S-transferase fusion protein containing NIS protein (amino acids 466-522) showed the NIS protein at 77 kD. The NIS protein level was elevated in 7 of 17 cases of papillary carcinoma but was not elevated in the normal thyroid. Immunohistochemical staining revealed abundant NIS in 8 of 12 carcinomas, whereas NIS protein was barely detected in specimens with normal thyroid. Although considerable patient-to-patient variation was observed, our results indicate that NIS mRNA is elevated, and its protein tends to be more abundant, in a subset of papillary thyroid carcinomas than in normal thyroid tissue.

Full Text

The Full Text of this article is available as a PDF (245.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abe Y., Ichikawa Y., Homma M., Ito K., Mimura T. T.S.H. receptor and adenylate cyclase in undifferentiated thyroid carcinoma. Lancet. 1977 Sep 3;2(8036):506–506. doi: 10.1016/s0140-6736(77)91629-4. [DOI] [PubMed] [Google Scholar]
  2. Arcangeli P., Toccafondi R., Rotella C. M., Aterini S., Tanini A., Borelli D., Loddi L. Dissociation in the response of the adenylate cyclase system to thyrotropin and prostaglandin E2 in human thyroid carcinoma tissue. Cancer. 1981 Aug 1;48(3):757–761. doi: 10.1002/1097-0142(19810801)48:3<757::aid-cncr2820480316>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  3. Carayon P., Thomas-Morvan C., Castanas E., Tubiana M. Human thyroid cancer: membrane thyrotropin binding and adenylate cyclase activity. J Clin Endocrinol Metab. 1980 Oct;51(4):915–920. doi: 10.1210/jcem-51-4-915. [DOI] [PubMed] [Google Scholar]
  4. Crile G., Jr Changing end results in patients with papillary carcinoma of the thyroid. Surg Gynecol Obstet. 1971 Mar;132(3):460–468. [PubMed] [Google Scholar]
  5. Dai G., Levy O., Carrasco N. Cloning and characterization of the thyroid iodide transporter. Nature. 1996 Feb 1;379(6564):458–460. doi: 10.1038/379458a0. [DOI] [PubMed] [Google Scholar]
  6. Dobyns B. M., Bertozzi G. Identification of cold thyroid lesions at operation and its place in the surgical management of carcinoma of the thyroid. Ann Surg. 1970 Oct;172(4):703–710. doi: 10.1097/00000658-197010000-00015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Edmonds C. J., Hayes S., Kermode J. C., Thompson B. D. Measurement of serum TSH and thyroid hormones in the management of treatment of thyroid carcinoma with radioiodine. Br J Radiol. 1977 Nov;50(599):799–807. doi: 10.1259/0007-1285-50-599-799. [DOI] [PubMed] [Google Scholar]
  8. Endo T., Kaneshige M., Nakazato M., Kogai T., Saito T., Onaya T. Autoantibody against thyroid iodide transporter in the sera from patients with Hashimoto's thyroiditis possesses iodide transport inhibitory activity. Biochem Biophys Res Commun. 1996 Nov 1;228(1):199–202. doi: 10.1006/bbrc.1996.1639. [DOI] [PubMed] [Google Scholar]
  9. Endo T., Kogai T., Nakazato M., Saito T., Kaneshige M., Onaya T. Autoantibody against Na+/I- symporter in the sera of patients with autoimmune thyroid disease. Biochem Biophys Res Commun. 1996 Jul 5;224(1):92–95. doi: 10.1006/bbrc.1996.0989. [DOI] [PubMed] [Google Scholar]
  10. Field J. B., Bloom G., Chou M. C., Kerins M. E., Larsen P. R., Kotani M., Kariya T., Dekker A. Effects of thyroid-stimulating hormone on human thyroid carcinoma and adjacent normal tissue. J Clin Endocrinol Metab. 1978 Nov;47(5):1052–1058. doi: 10.1210/jcem-47-5-1052. [DOI] [PubMed] [Google Scholar]
  11. Goldman J. M., Line B. R., Aamodt R. L., Robbins J. Influence of triiodothyronine withdrawal time on 131I uptake postthyroidectomy for thyroid cancer. J Clin Endocrinol Metab. 1980 Apr;50(4):734–739. doi: 10.1210/jcem-50-4-734. [DOI] [PubMed] [Google Scholar]
  12. Ichikawa Y., Saito E., Abe Y., Homma M., Muraki T. Presence of TSH receptor in thyroid neoplasms. J Clin Endocrinol Metab. 1976 Feb;42(2):395–398. doi: 10.1210/jcem-42-2-395. [DOI] [PubMed] [Google Scholar]
  13. Kaminsky S. M., Levy O., Salvador C., Dai G., Carrasco N. Na(+)-I- symport activity is present in membrane vesicles from thyrotropin-deprived non-I(-)-transporting cultured thyroid cells. Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3789–3793. doi: 10.1073/pnas.91.9.3789. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Kogai T., Endo T., Saito T., Miyazaki A., Kawaguchi A., Onaya T. Regulation by thyroid-stimulating hormone of sodium/iodide symporter gene expression and protein levels in FRTL-5 cells. Endocrinology. 1997 Jun;138(6):2227–2232. doi: 10.1210/endo.138.6.5189. [DOI] [PubMed] [Google Scholar]
  15. Kraiem Z., Sadeh O., Yosef M. Iodide uptake and organification, tri-iodothyronine secretion, cyclic AMP accumulation and cell proliferation in an optimized system of human thyroid follicles cultured in collagen gel suspended in serum-free medium. J Endocrinol. 1991 Dec;131(3):499–506. doi: 10.1677/joe.0.1310499. [DOI] [PubMed] [Google Scholar]
  16. Leeper R. D. The effect of 131 I therapy on survival of patients with metastatic papillary or follicular thyroid carcinoma. J Clin Endocrinol Metab. 1973 Jun;36(6):1143–1152. doi: 10.1210/jcem-36-6-1143. [DOI] [PubMed] [Google Scholar]
  17. Levy O., Dai G., Riedel C., Ginter C. S., Paul E. M., Lebowitz A. N., Carrasco N. Characterization of the thyroid Na+/I- symporter with an anti-COOH terminus antibody. Proc Natl Acad Sci U S A. 1997 May 27;94(11):5568–5573. doi: 10.1073/pnas.94.11.5568. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Maxon H. R., Thomas S. R., Hertzberg V. S., Kereiakes J. G., Chen I. W., Sperling M. I., Saenger E. L. Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med. 1983 Oct 20;309(16):937–941. doi: 10.1056/NEJM198310203091601. [DOI] [PubMed] [Google Scholar]
  19. Morris J. C., Kim C. K., Padilla M. L., Mechanick J. I. Conversion of non-iodine-concentrating differentiated thyroid carcinoma metastases into iodine-concentrating foci after anticancer chemotherapy. Thyroid. 1997 Feb;7(1):63–66. doi: 10.1089/thy.1997.7.63. [DOI] [PubMed] [Google Scholar]
  20. Ohta K., Endo T., Onaya T. The mRNA levels of thyrotropin receptor, thyroglobulin and thyroid peroxidase in neoplastic human thyroid tissues. Biochem Biophys Res Commun. 1991 Feb 14;174(3):1148–1153. doi: 10.1016/0006-291x(91)91540-s. [DOI] [PubMed] [Google Scholar]
  21. Paire A., Bernier-Valentin F., Selmi-Ruby S., Rousset B. Characterization of the rat thyroid iodide transporter using anti-peptide antibodies. Relationship between its expression and activity. J Biol Chem. 1997 Jul 18;272(29):18245–18249. doi: 10.1074/jbc.272.29.18245. [DOI] [PubMed] [Google Scholar]
  22. Pochin E. E. Prospects from the treatment of thyroid carcinoma with radioiodine. Clin Radiol. 1967 Apr;18(2):113–125. doi: 10.1016/s0009-9260(67)80001-1. [DOI] [PubMed] [Google Scholar]
  23. Roger P., Taton M., Van Sande J., Dumont J. E. Mitogenic effects of thyrotropin and adenosine 3',5'-monophosphate in differentiated normal human thyroid cells in vitro. J Clin Endocrinol Metab. 1988 Jun;66(6):1158–1165. doi: 10.1210/jcem-66-6-1158. [DOI] [PubMed] [Google Scholar]
  24. Saito T., Endo T., Kawaguchi A., Ikeda M., Nakazato M., Kogai T., Onaya T. Increased expression of the Na+/I- symporter in cultured human thyroid cells exposed to thyrotropin and in Graves' thyroid tissue. J Clin Endocrinol Metab. 1997 Oct;82(10):3331–3336. doi: 10.1210/jcem.82.10.4269. [DOI] [PubMed] [Google Scholar]
  25. Samaan N. A., Schultz P. N., Haynie T. P., Ordonez N. G. Pulmonary metastasis of differentiated thyroid carcinoma: treatment results in 101 patients. J Clin Endocrinol Metab. 1985 Feb;60(2):376–380. doi: 10.1210/jcem-60-2-376. [DOI] [PubMed] [Google Scholar]
  26. Schlumberger M., Charbord P., Fragu P., Gardet P., Lumbroso J., Parmentier C., Tubiana M. Relationship between thyrotropin stimulation and radioiodine uptake in lung metastases of differentiated thyroid carcinoma. J Clin Endocrinol Metab. 1983 Jul;57(1):148–151. doi: 10.1210/jcem-57-1-148. [DOI] [PubMed] [Google Scholar]
  27. Simon D., Köhrle J., Schmutzler C., Mainz K., Reiners C., Röher H. D. Redifferentiation therapy of differentiated thyroid carcinoma with retinoic acid: basics and first clinical results. Exp Clin Endocrinol Diabetes. 1996;104 (Suppl 4):13–15. doi: 10.1055/s-0029-1211692. [DOI] [PubMed] [Google Scholar]
  28. Smanik P. A., Liu Q., Furminger T. L., Ryu K., Xing S., Mazzaferri E. L., Jhiang S. M. Cloning of the human sodium lodide symporter. Biochem Biophys Res Commun. 1996 Sep 13;226(2):339–345. doi: 10.1006/bbrc.1996.1358. [DOI] [PubMed] [Google Scholar]
  29. Smanik P. A., Ryu K. Y., Theil K. S., Mazzaferri E. L., Jhiang S. M. Expression, exon-intron organization, and chromosome mapping of the human sodium iodide symporter. Endocrinology. 1997 Aug;138(8):3555–3558. doi: 10.1210/endo.138.8.5262. [DOI] [PubMed] [Google Scholar]
  30. Takahashi H., Jiang N. S., Gorman C. A., Lee C. Y. Thyrotropin receptors in normal and pathological human thyroid tissues. J Clin Endocrinol Metab. 1978 Oct;47(4):870–876. doi: 10.1210/jcem-47-4-870. [DOI] [PubMed] [Google Scholar]
  31. Varma V. M., Beierwaltes W. H., Nofal M. M., Nishiyama R. H., Copp J. E. Treatment of thyroid cancer. Death rates after surgery and after surgery followed by sodium iodide I-131. JAMA. 1970 Nov 23;214(8):1437–1442. doi: 10.1001/jama.214.8.1437. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES